Category Archives: BioUtah News

Clene Inc. announced on Monday that the company received a Healthy Longevity Catalyst Award from the U.S. National Academy of Medicine (NAM) to accelerate the preclinical development of CNM-Au8, a bioenergetic nanocatalyst, for treatment of neuronal aging-related deficits and Alzheimer’s disease. The international award will fund preclinical study of CNM-Au8 nanocatalysis for the improvement of human health […]

ARUP Laboratories on May 10 announced it has signed a strategic agreement with Massachusetts-based TellBio Inc. to use the company’s TellDx circulating tumor cells (CTCs) technology in several research applications. ARUP has also invested in TellBio as part of the startup’s series A financing round. Other funding partners include Crocker Ventures, Genetron Holdings Ltd (NASDAQ: […]

Xenter has announced the appointment of four additional industry leaders to its Board of Directors and the closing of a $12M Series A offering of preferred stock. “Xenter is transforming healthcare as an innovative Device-Data-Drug healthcare technologies startup,” said Kelvyn Cullimore, president and CEO of BioUtah. “The new additions to the board, including Utah life […]

IDbyDNA, the pioneer in precision metagenomics, has appointed Next-Generation Sequencing (NGS) leader Neil Gunn as its new CEO to drive the next phase of the company’s growth. “Having spent the last 12 years growing the PCR and sequencing businesses at Roche, I’m excited by the tremendous potential IDbyDNA’s platform has to transform the diagnostic approach to […]

This week SINTX Technoloiges announced multiple U.S. and international patent applications for development of new technologies utilizing the company’s silicon nitride. “The innovative application of SINTX’s silicon nitride promises new tools to improve our public health response to COVID-19 and other viruses,” said Kelvyn Cullimore, president and CEO of BioUtah. SINTX has found that its […]

Foldax was named by Fierce Medtech as one of the 2020 “Fierce 15,” designating it as one of the most promising private companies in the medical technology industry. “BioUtah congratulates Foldax on this well-deserved recognition, which is all the more impressive amid the challenges of a pandemic,” said Kelvyn Cullimore, president and CEO of BioUtah. Foldax […]

DiscGenics, a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine,  has completed enrollment in its Japanese safety study of Injectable Discogenic Cell Therapy (IDCT) for lumbar disc degeneration, a major cause of chronic low back pain. This Japanese 38-subject […]